ArticleFrontiers in oncology2022

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.

Di Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.